Literature DB >> 16635785

Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Rammurti T Kamble1, George B Selby, Martha Mims, Mohamed A Kharfan-Dabaja, Howard Ozer, James N George.   

Abstract

Iron overload presenting as exacerbation of hepatic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation has not been previously described. We report 6 patients with established hepatic GVHD in whom iron overload (median serum ferritin, 7231 mug/dL; median transferrin saturation, 77%) resulting from a lifetime median of 20 units of packed red blood cell transfusions was manifested by worsening of liver function. Liver biopsies performed in 4 patients confirmed severe iron overload and also hepatic GVHD. Analysis for the C282Y and H63D hemochromatosis gene mutation was negative for the homozygous state in all 6 patients. Erythropoietin-assisted phlebotomy resulted in normalization of liver function at a median of 7 months and of serum ferritin at a median of 11 months. Immunosuppressive therapy was successfully tapered in all 4 patients who completed the phlebotomy program, and this supported the impression that iron overload, rather than GVHD, was the principal cause of liver dysfunction. At a median follow-up of 50 months (range, 18-76 months) from the transplantation and 25 months (range, 5-36 months) from ferritin normalization, all 4 patients require maintenance phlebotomy. We conclude that iron overload can mimic GVHD exacerbation, thus resulting in unnecessary continuation or intensification of immunosuppressive therapy for GVHD, and that maintenance phlebotomy is necessary after successful iron-reduction therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635785     DOI: 10.1016/j.bbmt.2006.01.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

3.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

Review 4.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

5.  Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients.

Authors:  Tahereh Rostami; Seyed Mostafa Monzavi; Hossein Poustchi; Ali Reza Khoshdel; Maryam Behfar; Amir Ali Hamidieh
Journal:  Int J Hematol       Date:  2020-10-08       Impact factor: 2.490

6.  Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Authors:  A Sirvent; P Auquier; C Oudin; Y Bertrand; S Bohrer; P Chastagner; M Poirée; J Kanold; S Thouvenin; Y Perel; D Plantaz; M-D Tabone; K Yakouben; V Gandemer; P Lutz; N Sirvent; C Vercasson; J Berbis; H Chambost; G Leverger; A Baruchel; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

7.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

8.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

Review 9.  Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.

Authors:  H Joachim Deeg; Emily Spaulding; Howard M Shulman
Journal:  Leuk Lymphoma       Date:  2009-10

10.  Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice.

Authors:  Steven Bair; Emily Spaulding; Jaakko Parkkinen; Howard M Shulman; Vladimir Lesnikov; Mary Beauchamp; François Canonne-Hergaux; Kris V Kowdley; H Joachim Deeg
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.